Views & Analysis | Perspectives on pharma industry issues

Patients

Reshaping the future of patient-centric drug development

Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.

R&D

Changing Faces: Pharma and biotech hires, June & July 2026

In June/July, companies continued to reshape their leadership teams in preparation for upcoming clinical, regulatory, and commercial milestones.

Sales & Marketing

Sponsored

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

R&D

GLP-1 RAs in CKM management: A Q&A with CORXEL

GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.

Views & Analysis

An introduction to the new NIHR National Patient Recruitment...

A new network of patient recruitment centres is set to shape the future of commercial clinical trials in the UK by offering new approaches to conduct late-phase, large-scale research projec

Views & Analysis

What HCPs think about COVID-19’s impact on cancer

COVID-19’s knock-on effect on cancer patients is of concern by HCPs, with delayed or decreased diagnosis seen as a key worry. CREATION.co’s Lara Meyer explores why HCPs need more support.

Views & Analysis

Sharing experiences to level the healthcare playing field

Amanda Barrell speaks to Alfred Samuels on his experience of prostate cancer and diversifying clinical trials to include the Black, Asian and minority ethnic (BAME) community.

Sales & Marketing

Sponsored

Personalisation is the biggest lie brands keep telling

Pharma brands need to move beyond surface-level personalisation and focus on measurable impact.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Digital

Nurse affixes a smart device to an elderly patient's wrist

Smaller, smarter devices for global trial diversity

Consumer device giants are surging into the healthcare arena to make devices cheaper, more compact, and easier for patients to use.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs